JenKem Technology Co., Ltd.

Main purpose Evaluate the safety and tolerability of polyethylene glycol irinotecan for injection combined with temozolomide in subjects with glioma Secondary purpose 1) Preliminary observation of the effectiveness of polyethylene glycol irinotecan for injection combined with temozolomide in subjects with glioma, and provide a basis for the recommended dose and administration method for subsequent clinical trials 2) Investigate the pharmacokinetic characteristics of polyethylene glycol irinotecan for injection combined with temozolomide in subjects with glioma, and obtain the pharmacokinetic parameters after combined administration

Primary objectives: 1) To evaluate the safety and tolerability of JK1201I in patients with small cell lung cancer; 2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of JK1201I. Secondary objectives: 1) To investigate the pharmacokinetic properties of JK1201I in patients with small cell lung cancer; 2) To observe the preliminary efficacy of JK1201I.

The primary objectives are to evaluate the safety and tolerability of polyethylene glycol irinotecan for injection in patients with malignant solid tumors and to determine its dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). The secondary objectives are to investigate its pharmacokinetic properties in patients with malignant solid tumors and obtain pharmacokinetic parameters; to observe the preliminary efficacy of polyethylene glycol irinotecan for injection and provide a basis for the recommended dose and administration method for subsequent clinical trials.